Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

HD18 for Advanced Stages in Hodgkins Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne
ClinicalTrials.gov Identifier:
NCT00515554
First received: August 10, 2007
Last updated: November 7, 2016
Last verified: November 2016
  Purpose

This study is designed to test:

  1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
  2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.

Condition Intervention Phase
Hodgkins Lymphoma
Drug: Rituximab
Drug: BEACOPP escalated
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Prof. Dr. Andreas Engert, University of Cologne:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 5 years ]
  • acute toxicity [ Time Frame: 5 years ]
  • late toxicity [ Time Frame: 5 years ]
  • CR-rate [ Time Frame: 5 years ]

Estimated Enrollment: 1500
Study Start Date: May 2008
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
8 cycles BEACOPPesc
Drug: BEACOPP escalated
chemotherapy with BEACOPP escalated
Experimental: B
8 cycles BEACOPPesc plus rituximab
Drug: Rituximab
addition of Rituximab to BEACOPP escalated
Drug: BEACOPP escalated
chemotherapy with BEACOPP escalated
Active Comparator: C
8 cycles BEACOPPesc
Drug: BEACOPP escalated
chemotherapy with BEACOPP escalated
Experimental: D
4 cycles BEACOPPesc
Drug: BEACOPP escalated
chemotherapy with BEACOPP escalated

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hodgkin Lymphoma (histologically proven)
  • CS (PS) IIB with one or both of the risk factors:

    • bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
    • extranodal involvement
  • CS (PS) III, IV
  • Written informed consent

Exclusion Criteria:

  • Leucocytes < 3000/µl
  • Platelets < 100000/µl
  • Hodgkin´s lymphoma as "composite lymphoma"
  • Activity index (WHO) < grade 2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00515554

Locations
Germany
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany, 50924
Sponsors and Collaborators
University of Cologne
Investigators
Principal Investigator: Andreas Engert, Prof. University of Cologne
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. Andreas Engert, Prof., University of Cologne
ClinicalTrials.gov Identifier: NCT00515554     History of Changes
Other Study ID Numbers: HD18
Study First Received: August 10, 2007
Last Updated: November 7, 2016

Keywords provided by Prof. Dr. Andreas Engert, University of Cologne:
Hodgkin lymphoma
PET
advances stages
Rituximab

Additional relevant MeSH terms:
Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 25, 2017